New AACE Guidelines for Non-Alcoholic Fatty Liver Disease - Frankly Speaking Ep 302

<p>Credits: 0.25 AMA PRA Category 1 Credit™  </p> <p> </p> <p>CME/CE Information and Claim Credit: <a href='https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-302'>https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-302</a></p> <p> </p> <p>Overview: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States, with a prevalence rate of more than 30% of US adults. Most have not been diagnosed or treated. Join us to discuss the new AACE guidance on the diagnosis and treatment of NAFLD to reduce the burden of this common disease.</p> <p> </p> <p>Episode resource links:</p> <ul><li>AACE Guideline:  Endocrine Pract: May 2022, 28(5): 528-562</li> <li>Coffee: Front Pharmacol. 2021 Dec 13;12:786596. doi: 10.3389/fphar.2021.786596</li> </ul> <p> </p> <p>Guest: Robert A. Baldor, MD</p> <p> </p> <p>Music Credit: Richard Onorato  </p>